Darden, Douglas
Aldaas, Omar
Malladi, Chaitanya L.
Mylavarapu, Praneet S.
Munir, Muhammad Bilal
Han, Frederick T.
Hoffmayer, Kurt S.
Raissi, Farshad
Ho, Gordon
Krummen, David
Feld, Gregory K.
Hsu, Jonathan C. http://orcid.org/0000-0002-1523-573X
Article History
Received: 13 December 2020
Accepted: 26 March 2021
First Online: 7 April 2021
Declarations
:
: The study was approved by the Institutional Review Board of University of California, San Diego.
: Dr. Hsu reports receiving honoraria from Medtronic, Abbott, Boston Scientific, Biotronik, Janssen Pharmaceuticals, Bristol-Myers Squibb, Altathera Pharmaceuticals, Zoll Medical, and Biosense-Webster; equity in Acutus Medical and Vektor Medical; and research grants from Biotronik and Biosense-Webster. Dr. Ho receives grant support from the American Heart Association (AHA 19CDA34760021), National Institutes of Health (NIH 1KL2TR001444), and reports equity in Vektor Medical Inc. unrelated to this work. Dr. Krummen reports receiving a research grant from the University Galvanizing Engineering in Medicine Foundation, equity in Vektor Medical unrelated to the present work, and fellowship support from Abbott, Biosense-Webster, Biotronik, Boston Scientific, and Medtronic. Dr. Feld reports equity in Acutus Medical, Inc., Vektor Medical, Inc., and Perminova, Inc.; has received honoraria from Altathera Pharmaceuticals, Inc., Vektor Medical, Inc., and Acutus Medical, Inc.; and, as EP Fellowship Training Program Director, indirectly receives fellowship stipend support from Abbott, Inc., Boston Scientific, Inc., Biotronik, Inc., and Biosense Webster, Inc.